PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
118.91%
Cash & equivalents growing 118.91% while AGEN's declined -13.29%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
118.91%
Below half of AGEN's -13.29%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.59%
Below half of AGEN's -8.66%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
15.06%
Below half AGEN's 89.56%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Less than half of AGEN's -39.40%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
15.06%
0.5-0.75x AGEN's 21.67%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
104.51%
≥ 1.5x AGEN's 7.60%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
55.57%
Above 1.5x AGEN's 35.68%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
719.98%
Exceeding 1.5x AGEN's 82.93%. Michael Burry suspects ballooning short-term obligations vs. competitor.
14812.60%
Less than half of AGEN's -89.39%. David Dodd sees a more disciplined short-term liability approach.
-100.00%
Less than half of AGEN's 1.19%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of AGEN's 3.28%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4364.90%
Above 1.5x AGEN's 2.89%. Michael Burry sees a potential leverage warning sign.
91.77%
Above 1.5x AGEN's 0.07%. Michael Burry suspects heavy new equity expansion or dilution.
-19849.13%
≥ 1.5x AGEN's -0.89%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1201.65%
Below half AGEN's -33.77%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.16%
Above 1.5x AGEN's 1.16%. Michael Burry sees a major jump. Investigate leverage rationale.
-119.69%
Less than half of AGEN's 34.45%. David Dodd sees better deleveraging or stronger cash buildup than competitor.